Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-01-25
2005-01-25
Nguyen, Dave T. (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100, C435S455000, C424S482000
Reexamination Certificate
active
06846809
ABSTRACT:
The present invention relates generally to the fields of nucleic acid transfection. More particularly, it concerns novel polycation:nucleic acid compositions, methods of preparation of such compositions and methods of transfecting cells with such compositions.
REFERENCES:
patent: 5260002 (1993-11-01), Wang
patent: 5354844 (1994-10-01), Beug et al.
patent: 5462866 (1995-10-01), Wang
patent: 5494682 (1996-02-01), Cohen et al.
patent: 5641656 (1997-06-01), Sekellick et al.
patent: 5656611 (1997-08-01), Kabanov et al.
patent: 5792645 (1998-08-01), Beug et al.
patent: 5824654 (1998-10-01), Lavie et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5908777 (1999-06-01), Lee et al.
patent: 5972600 (1999-10-01), Szoka, Jr. et al.
patent: 6071533 (2000-06-01), Papahadjopoulos et al.
patent: 6071741 (2000-06-01), Wong et al.
patent: 6083741 (2000-07-01), Hart et al.
patent: 6113946 (2000-09-01), Szoka, Jr. et al.
patent: 6313285 (2001-11-01), Butler et al.
patent: 6506890 (2003-01-01), Cooper et al.
patent: 20010005717 (2001-06-01), Wagner
patent: 20010006817 (2001-07-01), Pack
patent: 20030026841 (2003-02-01), Trubetskoy et al.
patent: WO 9611671 (1996-04-01), None
Kircheis, Advanced Drug Delivery Reviews, 53, 341-358, 2001.*
Schatzlein, Anti-Cancer Drugs, 12, pp. 275-304, 2001.*
Mendiratta, Human Gene Therapy, 11:1851-1862, 2000.*
Horn, Human Gene Therapy, 6:565-573, 1995.*
Monteiro, Biotechnol Bioeng 66:189-194, 1999.*
Gomez-Navarro et al., Eropean J of Cancer, vol. 35, No. 6, pp. 867-885, 1999.*
Meng et al. (Gene Therapy of Cancer, Chapter I, pp. 3-20, 1999).*
Plenat (Molecular Medicine Today, vol. 1, 3, 1996, pp. 250-257).*
Anderson (Nature, vol. 292, 25-30, 1998).*
Verma et al. (Nature, vol. 389, pp. 239-242, 1997).*
Blessing et al., “Different strategies for formation of PEGylated EGF-conjugated PEI/DNA complexes for targeted gene delivery,”Bioconjugate Chem.,12:529-537, 2001.
Hart, “Synthetic vectors for gene therapy,”Expert Opinion on Therapeutic Patents,10(2):199-208, 2000.
Bendas et al., “Targetability of novel immunoliposomes prepared by a new antibody conjugation technique,”Int. J. Pharm.,181:79-93, 1999.
Boletta et al., “Nonviral gene delivery to the rat kidney with polyethylenimine,”Human Gene Therapy,8:1243-1251, 1997.
Bousiff et al., “A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: Polyethylenimine,”Proc. Natl. Acad. Sci. USA,92:7297-7301, 1995.
Boussif et al., “Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold,”Gene Therapy,3:1074-1080, 1996.
Chen et al., “Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene,”Cancer Research,60(4):1035-1042, 2000.
Coll et al., “In vivo delivery to tumors of DNA complexed with linear polyethylenimine,”Human Gene Therapy,10(10):1659-1666, 1999.
Cristiano and Roth, “Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor,”Cancer Gene Therapy,3:4-10, 1996.
Cristiano and Roth, “Molecular conjugates: a targeted gene delivery vector for molecular medicine,”J. Mol. Med.,73:479-486,1995.
Densmore et al., “Aerosol delivery of robust polyethylenimine-DNA complexes for gene therapy and genetic immunization,”Molecular Therapy,1:180-188, 2000.
Fraley et al., “Entrapment of a bacterial plasmid in phospholipid vesicles: potential for gene transfer,”Proc. Natl. Acad. Sci. USA,76:3348-3352, 1979.
Fronsdal et al., “Efficient DNA-mediated gene transfer into prostate cancer cell line LNCaP,”Prostate,43(2):111-117, 2000.
Gao et al., “Direct in vivo gene transfer to airway epithelium employing adenovirus-polylysine-DNA complexes,”Human Gene Therapy,4:17-23, 1993.
Goula et al., “Polyethylenimine-based intravenous delivery of transgenes to mouse lung,”Gene Therapy,5(9):1291-1295,1998.
Kircheis et al., “Coupling of cell binding ligands to polyethylenimine for targeted gene delivery,”Gene Therapy,4:409-418, 1997.
Li et al., “Assesment of recombinant adenoviral vectors for hepatic gene therapy,”Hum Gene Ther.,4:403-409, 1993.
Li, et al., “Synthesis and evaluation of water-soluble polyethylene glycol paclitaxel conjugate as a paclitaxel prodrug,”Anti-Cancer Drugs,7:642-648, 1996.
Marshall, “Clinical trails—Gene therapy death prompts reviews of adenovirus vector,”Science,286(5448):2244-2245, 1999.
Nicolau and Sene, “Liposome-mediated DNA transfer in eukaryotic cells. Dependence of the transfer efficiency upon the type of liposomes used and the host cell cycle stage,”Biochim Biophys. Acta,721:185-190, 1982.
Nicolau et al., “Liposomes as carriers for in vivo gene transfer and expression,”Methods Enzymol.,149:157-176, 1987.
Plum et al., “Condensation of DNA by trivalent cations. 2. Effects of cation structure,”Biopolymers,30: 631:643, 1990.
Rosenberg et al., “Human gene marker/therapy clinical protocols,”Human Gene Therapy,11(6):919-979, 2000.
Rudolph et al., “In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers,”J. Gene Med.,2(4):269-278, 2000.
Smyth Templeton et al., “Improved DNA: liposome complexes for increased systemic delivery and gene expression,”Nature Biotech.,15(7):647-652, 1997.
Tomalia et al., “Starburst dendrimers: molecular-level control of size, shape, surface chemistry, topology, and flexibility from atoms to macroscopic matter,”Angew. Chem. Int. Ed. Engl.,29:138-175, 1990.
Xu et al., “The contribution of poly-L-lysine, streptavidin, and epidermal growth factor to EGF/PLL/DNA polyplex formation,”Gene Therapy,5:1235-1243, 1998.
Cristiano Richard J.
Yamashita Motoyuki
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Nguyen Dave T.
LandOfFree
PEI: DNA vector formulations for in vitro and in vivo gene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with PEI: DNA vector formulations for in vitro and in vivo gene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and PEI: DNA vector formulations for in vitro and in vivo gene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3376097